Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients.

ABSTRACT: BACKGROUND:5-Fluorouracil (5-FU) and capecitabine are fluoropyrimidine derivatives that mainly metabolized with dihydropyrimidine dehydrogenase enzyme (DPD). The genetic polymorphism in the genes encoding this enzyme may result in a decrease or loss of enzyme activity which may lead to the accumulation of medicines, their metabolites and potential toxicity. METHOD:This cross-sectional study was conducted on 88 participants with colorectal cancer (CRC). After DNA extraction, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used to determine the DPD gene (DPYD) polymorphisms including IVS 14?+?1?G?>?A, 2846 A?>?T and 2194?G?>?A. Chemotherapy-induced side effects were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE Version 5.0). RESULT:Data were collected from 227 chemotherapy cycles of 88 patients with CRC. In a comparison of FOLFOX and FOLFIRI regimens, there was no significant difference in the occurrence of chemotherapy-induced diarrhea, nausea, vomiting and oral mucositis. However, the peripheral neuropathy was more frequent in patients who were treated with FOLFOX (P??A polymorphism was observed in four patients (5.5%). There was no association between IVS14?+?1?G?>?A polymorphism and the occurrence of adverse reactions. CONCLUSION:FOLFOX and FOLFIRI were the most common regimens in CRC patients and their toxicity profile was different in some adverse reactions. Prevalence of IVS14?+?1G?>?A variant was relatively higher than other similar studies. TRIAL REGISTRATION:Approval code; IR.MAZUMS.REC.95.2480.

SUBMITTER: Negarandeh R 

PROVIDER: S-EPMC7298798 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature